Advertisement

Topics

Pfizer, Merck KGaA lung cancer drug fails

05:16 EST 15 Feb 2018 | BioPharmaDive

The duo's checkpoint inhibitor Bavencio failed to beat out chemotherapy in the key setting of non-small cell lung cancer

Original Article: Pfizer, Merck KGaA lung cancer drug fails

NEXT ARTICLE

More From BioPortfolio on "Pfizer, Merck KGaA lung cancer drug fails"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...